NextTrip (NTRP) 10-K 1 Apr 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 27, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	SIGMA LABS, INC.
Entity Central Index Key	0000788611
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 7,856,465
Entity Common Stock, Shares Outstanding		10,537,590
Trading Symbol	SGLB
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash	$ 1,279,782	$ 1,515,674
Accounts Receivable, net	38,800	104,538
Note Receivable, net	121,913	788,500
Inventory	240,086	192,705
Prepaid Assets	67,255	55,278
Total Current Assets	1,747,836	2,656,695
Other Assets:
Property and Equipment, net	277,944	411,643
Intangible Assets, net	404,978	294,396
Investment in Joint Venture	500	500
Prepaid Stock Compensation		31,576
Total Other Assets	683,422	738,115
TOTAL ASSETS	2,431,258	3,394,810
Current Liabilities:
Accounts Payable	217,488	100,884
Note Payable	50,000	100,000
Deferred Revenue	51,498	35,680
Accrued Expenses	376,833	146,330
Total Current Liabilities	695,819	382,894
Long-Term Liabilities
TOTAL LIABILITIES	695,819	382,894
Commitments & Contingencies
Stockholders' Equity
Preferred Stock, $0.001 par; 10,000,000 shares authorized; None issued and outstanding
Common Stock, $0.001 par; 22,500,000 shares authorized; 8,776,629 and 4,978,929 issued and outstanding, respectively	8,777	4,979
Additional Paid-In Capital	21,501,407	17,192,394
Accumulated Deficit	(19,774,745)	(14,185,457)
Total Stockholders' Equity	1,735,439	3,011,916
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,431,258	$ 3,394,810

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	22,500,000	22,500,000
Common stock, shares issued	8,776,629	4,978,929
Common stock, shares outstanding	8,776,629	4,978,929

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
REVENUES	$ 388,574	$ 641,049
COST OF REVENUE	270,107	272,372
GROSS PROFIT	118,467	368,677
EXPENSES:
Salaries & Benefits	2,056,584	1,509,672
Stock-Based Compensation	1,145,530	719,796
Operating R&D Costs	493,410	302,043
Investor & Public Relations	633,035	554,990
Legal & Professional Service Fees	564,854	563,300
Office Expenses	466,657	324,920
Depreciation & Amortization	192,374	196,943
Other Operating Expenses	134,827	95,990
Total Operating Expenses	5,687,271	4,267,654
LOSS FROM OPERATIONS	(5,568,804)	(3,898,977)
OTHER INCOME (EXPENSE)
Interest Income	35,178	40,107
State Incentives		154,568
Change in fair value of derivative liabilities		(186,908)
Exchange Rate Gain (Loss)	162
Interest Expense	(3,966)	(161,852)
Loss on Disposal of Assets	(36,733)	(13,161)
Debt discount amortization		(358,280)
Total Other Income (Expense)	(5,359)	(525,526)
LOSS BEFORE PROVISION FOR INCOME TAXES	(5,574,163)	(4,424,503)
Provision for Income Taxes
Net Loss	(5,574,163)	(4,424,503)
Preferred Dividends	(15,125)
Net Loss applicable to Common Stockholders	$ (5,589,288)	$ (4,424,503)
Net Loss per Common Share - Basic and Diluted	$ (.81)	$ (1)
Weighted Average Number of Shares Outstanding - Basic and Diluted	6,898,047	4,403,479

Statement of Stockholders' Equi

Statement of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016	$ 3,135	$ 10,734,857	$ (9,760,954)	$ 977,038
Balance, shares at Dec. 31, 2016	3,133,789
Shares issued for services - net of forfeitures	$ 32	75,546		75,578
Shares issued for services - net of forfeitures, shares	32,684
Fractional shares issued at reverse stock split	$ 1			1
Fractional shares issued at reverse stock split, shares	1,178
Shares and warrants sold in public offering, net of offering costs	$ 1,410	5,071,226		5,072,636
Shares and warrants sold in public offering, net of offering costs, shares	1,410,000
Shares issued from exchange of unit purchase options	$ 141	(141)
Shares issued from exchange of unit purchase options, shares	141,000
Shares issued for note & accrued interest conversion	$ 204	408,352		$ 408,556
Shares issued for note & accrued interest conversion, shares	204,278
Shares issued from exercise of warrants	$ 56	111,944		112,000
Shares issued from exercise of warrants, shares	56,000
Write-off of derivative liability - note conversions		280,114		280,114
Stock based compensation		510,496		510,496
Net loss			(4,424,503)	(4,424,503)
Balance at Dec. 31, 2017	$ 4,979	17,192,394	(14,185,457)	3,011,916
Balance, shares at Dec. 31, 2017	4,978,929
Shares issued for services - net of forfeitures	$ 200	256,064		256,264
Shares issued for services - net of forfeitures, shares	200,000
Shares and warrants sold in public offering, net of offering costs	$ 2,040	1,720,360		$ 1,722,400
Shares and warrants sold in public offering, net of offering costs, shares	2,040,000
Shares issued from exchange of unit purchase options, shares
Shares issued for note & accrued interest conversion	$ 25	49,975		$ 50,000
Shares issued for note & accrued interest conversion, shares	25,000
Shares issued from exercise of warrants	$ 178	191,954		192,132
Shares issued from exercise of warrants, shares	177,900
Stock based compensation		868,015		868,015
Convertible preferred shares sold		1,224,000		1,224,000
Shares issued for conversion of preferred	$ 1,350	(1,350)
Shares issued for conversion of preferred, shares	1,350,000
Shares issued for cashless exchange of warrants	$ 5	(5)
Shares issued for cashless exchange of warrants, shares	4,800
Preferred dividends paid upon conversion			(15,125)	(15,125)
Net loss			(5,574,163)	(5,574,163)
Balance at Dec. 31, 2018	$ 8,777	$ 21,501,407	$ (19,774,745)	$ 1,735,439
Balance, shares at Dec. 31, 2018	8,776,629

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
OPERATING ACTIVITIES
Net Loss	$ (5,574,163)	$ (4,424,503)
Noncash Expenses:
Depreciation and Amortization	192,374	196,943
Stock Based Compensation	1,145,530	719,796
Loss on Write-off of Asset	36,733	13,161
Refund on Write-off of Asset		15,700
Loss on Change in Derivative Balance		186,908
Original Issue Discount Amortization		88,442
Debt Discount Amortization		358,280
Change in assets and liabilities:
Accounts Receivable	65,738	183,698
Interest Receivable	34,390
Inventory	(24,844)	(5,464)
Prepaid Assets	(1,652)	(16,957)
Accounts Payable	116,604	(11,291)
Deferred Revenue	15,818	32,365
Accrued Expenses	230,501	24,529
NET CASH USED IN OPERATING ACTIVITIES	(3,762,971)	(2,638,393)
INVESTING ACTIVITIES
Purchase of Property and Equipment	(79,116)	(69,463)
Purchase of Intangible Assets	(149,409)	(70,997)
Advance of Funds for Notes Receivable		(788,500)
Payment Received from Notes Receivable	632,197
NET CASH (PROVIDED BY) INVESTING ACTIVITIES	403,672	(928,960)
FINANCING ACTIVITIES
Gross Proceeds from issuance of Convertible Preferred and Warrants	1,350,000
Gross Proceeds from issuance of Common Stock and Warrants	2,040,100	5,823,300
Less Offering Costs	(443,700)	(750,664)
Payments on Notes Payable		(500,000)
Proceeds from exercise of Warrants	192,132	112,000
Dividends on Preferred	(15,125)
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,123,407	4,684,636
NET CHANGE IN CASH FOR PERIOD	(235,892)	1,117,283
CASH AT BEGINNING OF PERIOD	1,515,674	398,391
CASH AT END OF PERIOD	1,279,782	1,515,674
Noncash investing and financing activities disclosure:
Write-off of Derivative Liability		(280,114)
Conversion of Convertible Debt for Stock	(50,000)	(408,556)
Common Stock Issued for Conversion of Series B&C Preferred	1,350
Common Stock Issued for Cashless Exchange of Warrants	5
Other noncash operating activities disclosure:
Issuance of Common Stock for services	256,264	75,578
Interest	12,205	89,348
Income Taxes

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 1 – Summary of Significant Accounting Policies Nature of Business Basis of Presentation Reclassification Continuing Operations – As a result, the Company currently has sufficient cash and working capital to fund operations through the end of the third quarter of 2019 and is anticipating that Phase II proof of concept contracts may be closed in the second and third quarter of fiscal 2019 generating additional cash flow in the near term. In addition, the Company has access to public and private markets from which to derive additional financing to sustain operations beyond that term, if required. Loss Per Share – Property and Equipment – In accordance with its policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis. This review in 2017 indicated that the actual useful life of the leasehold improvements the Company made to the leased facilities at 3900 Paseo del Sol, Santa Fe, New Mexico in 2014, is less than the fifteen-year estimated useful life that was being used for depreciation purposes in the Company’s financial statements. As a result, effective January 1, 2017, the Company changed the estimated useful life of these improvements to seven years. The effect of this change in estimate was to increase 2017 depreciation expense by $12,291. Fair Value of Financial Instruments . ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying amounts reported in the balance sheets for the cash and cash equivalents, prepaid stock compensation, receivables, accounts payable, and accrued liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. Although the Company had no other financial instruments requiring fair value disclosures, during 2017, the company wrote off a $93,206 fair value amount of a derivative liability balance from December 31, 2016. The derivative liability was the result of the original $1 million of Notes, and the 80,000 warrants, that were issued in October 2016, both of which contain anti-dilution provisions in the event the Company engages in specified transactions which occurred in February 2017. As a result, the instruments no longer required derivative treatment and were written off in February 2017. The following table presents a reconciliation of the derivative liability measured at fair value on a recurring basis using significant unobservable input (Level 3): Notes & Warrants Balance December 31, 2016 $ 93,206 Change in fair value 186,908 Write-off of derivative (280,114 ) Balance December 31, 2017 $ - During 2018 there were no instruments measured at fair value on a recurring basis. Income Taxes – The Company has no tax positions at December 31, 2018 and 2017 for which the ultimate deductibility is highly uncertain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the years ended December 31, 2018 and 2017, the Company recognized no interest and penalties. All tax years starting with 2015 are open for examination. Accounts Receivable and Allowance for Doubtful Accounts Long-Lived and Intangible Assets Cash Equivalents Concentration of Credit Risk - Stock Based Compensation Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No. 505, “Equity Based Payments to Non-Employees.” In general, the measurement date is either (a) when a performance commitment, as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification. Amortization Accounting Estimates Revenue Recognition – Revenue from Contracts with Customers We adopted this new revenue recognition standard along with is related amendments on January 1, 2018 and have updated our accounting policy for revenue recognition. As expected, at our current level of revenue, the adoption of this new standard did not impact our financial position or results of operations operating cash flows. In general, we determine revenue recognition by: (1) identifying the contract, or contracts, with our customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to performance obligations in the contract; and (5) recognizing revenue when, or as, we satisfy performance obligations by transferring the promised goods or services. Deferred Stock Offering Costs Inventory Research and Development

Notes Receivable

Notes Receivable	12 Months Ended
	Dec. 31, 2018
Receivables [Abstract]
Notes Receivable	NOTE 2 - Notes Receivable On May 1, 2017, the Company made a loan in the principal amount of $250,000 to Jaguar Precision Machine, LLC, a New Mexico limited liability company, pursuant to a Secured Convertible Promissory Note dated May 1, 2017 delivered by Jaguar to the Company. The loan bore interest at the rate of 7% per annum, was due and payable in full on May 1, 2018, was secured by certain assets of Jaguar, and is convertible at the Company’s option into 10% of the outstanding shares of the common stock of Jaguar unless Jaguar exercises its right under specified circumstances to repay all principal and accrued interest on the loan. The purpose of the loan was to provide working capital to Jaguar to, among other things, start up a metallurgical laboratory and become ASM9100 certified for contracts related to AM of high-precision aerospace and defense components, in furtherance of our strategic alliance. Sigma received from Jaguar priority for use of certain machines and services of Jaguar. On April 27, 2018, the promissory note was amended whereby the due date of the note was extended to June 1, 2018 in exchange for a cash payment of $5,000 received on May 1, 2018, 50% of which will be retained as payment for the 30-day extension. On June 6, 2018 the promissory note was amended whereby the due date was extended to August 1, 2018 in exchange for cash payments of $10,000 by each of June 7, 2018 and July 1, 2018, $8,000 of which is to be retained as payment for the 60-day extension. The first of the $10,000 payments was received by the Company on June 6, 2018. On June 15, 2018, the Company received a $150,000 payment from Jaguar, $17,803 of which was applied to accumulated interest through that date and $132,197, the balance, of which, was applied to the principal balance of the note. The holder of the promissory note has committed to paying the remaining principal balance along with accumulated interest on or before April 15, 2019. The December 31, 2018 principal balance of the note was $117,803 and the accumulated interest balance due was $4,110. On March 27, 2017, the Company made a loan in the principal amount of $500,000 bearing interest at the rate of 7% per annum to Morf3D, Inc., an Illinois corporation, pursuant to a Secured Convertible Promissory Note dated March 27, 2017 delivered by Morf3D to the Company. The $500,000 loan principal and $35,000 of accumulated interest was paid in full on March 17, 2018.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory	NOTE 3 - Inventory At December 31, 2018 and December 31, 2017, the Company’s inventory was comprised of: December 31 2018 December 31, 2017 Raw Materials $ 168,623 $ 127,076 Work in Process 46,688 251 Finished Goods 24,775 65,378 Total Inventory $ 240,086 $ 192,705

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 4 – Property and Equipment The following is a summary of property and equipment, purchased, used and depreciated over a five year period, less accumulated depreciation, as of December 31, 2018 and 2017: Year Ended December 31, 2018 2017 Property and Equipment $ 1,074,888 $ 1,027,966 Less: Accumulated Depreciation (796,944 ) (616,322 ) Net Property and Equipment $ 277,944 $ 411,643 Depreciation expense on property and equipment was $190,280 and $193,892 for the years ended December 31, 2018 and 2017, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 5 – Intangible Assets The Company’s intangible assets consist of Patents and Patent Pending Applications. Provisional patent applications are not amortized until a patent has been granted. Once a patent is granted, the Company will amortize the related costs over the estimated useful life of the patent. If a patent application is denied, then the costs will be expensed at that time. During 2018, the Company wrote off $37,649 of issued patent cost and $13,522 of related accumulated amortization along with $12,606 of provisional patent application cost as a result of the Company’s decision to abandon one patent and three pending patent applications that were specific to medical implants. In addition, $25,021 of cost related to the patent issued to us on June 19, 2018 was reclassified from provisional patent application to patent status and began to be amortized as of the date of issue. The following is a summary of definite-life intangible assets less accumulated amortization as of December 31, 2018 and 2017, respectively: Year Ended December 31, 2018 2017 Provisional Patent Applications $ 366,353 $ 254,570 Patents 47,073 59,701 Less: Accumulated Amortization (8,448 ) (19,875 ) Net Intangible Assets $ 404,978 $ 294,396 Amortization expense on intangible assets was $2,094 and $3,051 for the years ended December 31, 2018 and 2017. The estimated aggregate amortization expense for each of the succeeding years ending December 31 is as follows: 2019 $ 2,769 2020 2,769 2021 2,769 2022 2,769 Thereafter 27,549 $ 38,625

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Notes Payable	NOTE 6 - Notes Payable On September 29, 2017, the Company entered into amendments (the “Amendments”) to the October 17, 2016 Secured Convertible Promissory Notes and Warrants to purchase shares of the Company’s common stock, pursuant to which, among other things set forth in the Amendments, (1) the exercise price of the Warrants was reduced from $4.13 per share to $2.00 per share, and (2) the conversion price of the Notes was reduced from $4.13 per share to $2.00 per share. Under the Amendments, we paid the Holders an aggregate amount equal to $500,000 (representing 50% of the outstanding principal balance of the Notes) plus all accrued interest on the Notes. In consideration of the foregoing, the Holders agreed to, among other things, extend the payment date of the remaining 50% of the outstanding principal balance of the Notes from October 17, 2017 to the earlier of May 18, 2018 or the closing of our next underwritten public offering of securities in which we raise gross proceeds of at least $3,000,000 (should we elect to commence and close such an offering of securities). In December 2017, the Holders Converted $400,000 of the $500,000 Notes principal and $8,556 of accrued interest on one of the notes into 204,278 shares of common stock and exercised 56,000 of the warrants $2.00 per share for 56,000 additional shares of common stock. In April 2018, the Company entered into an amendment of the remaining $100,000 Note which extended the payment due date to October 18, 2018, deleted the covenant providing for acceleration of the payment due date in the event of a public offering closing of at least $3,000,000 and required the Company to pay the balance of accrued and unpaid interest as of the effective date of the amendment. The Company paid the $8,761 balance of accrued interest to the holder in April 2018. In May 2018 the Holder Converted $50,000 of the Note principal into 25,000 shares of common stock and executed a cashless exercise of 24,000 of the warrants for an additional 4,800 shares of common stock. In October 2018, the Note was amended pursuant to which the due date was extended to April 18, 2019. Under the amendment, Sigma paid the $3,444 total accrued interest balance as of October 18, 2018 and agreed to make future payment dates of accrued interest on December 31, 2018 and April 18, 2019. At December 31, 2018 the Company had the remaining $50,000 Convertible Note outstanding plus accrued interest of $1,028. The accrued interest amount was paid to the holder in January 2019.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Equity	NOTE 7 – Stockholders’ Equity Common Stock Effective February 15, 2017, our Articles of Incorporation were amended to provide for a reverse stock split of the outstanding shares of our common stock on a 1-for-2 basis (the “Reverse Stock Split”), and a corresponding decrease in the number of shares of our common stock that we are authorized to issue (the “Share Decrease”). The effects of the stock split have been retroactively reflected to all periods presented. Effective March 5, 2018, the Articles of Incorporation were again amended to increase the authorized number of shares of common stock to 15,000,000. Effective October 18, 2018, the Articles of Incorporation were again amended to increase the authorized number of shares of common stock to 22,500,000. In 2018, the Company issued 200,000 shares of common stock to directors valued at $1.28 per share, or $256,264. In May 2018, we issued an aggregate of 1,000,000 shares of common stock upon conversion of the 1,000 shares of Series B Preferred Stock issued in April 2018 (as described below under “Preferred Stock”). In May 2018, the Company issued 29,800 shares of common stock as the result of a conversion of the $50,000 principal balance of Notes Payable and the cashless exercise of 24,000 warrants. In June 2018, as part of its public offering of equity securities described in Note 1, the Company issued 350 shares of Series C convertible preferred stock, 2,040,000 shares of common stock, and warrants to purchase a total of 717,000 shares of common stock (including the warrants described under “Preferred Stock” below that were issued on June 26, 2018). Each warrant has an initial price of $1.08 per share. The net proceeds to the Company were approximately $2,068,900 after commissions and other offering expenses. The Company also issued to Dawson James Securities, Inc., its placement agent in the public offering, a Unit Purchase Option to acquire up to 191,200 Units, at an exercise price of $1.25 per Unit, consisting of 191,200 shares of common stock and warrants to purchase up to 57,360 shares of common stock at an exercise price of $1.08 as compensation. Between August and October 2018, the Company issued 350,000 shares of common stock upon conversion of 350 shares of Series C Preferred Stock issued in June 2018 (as described below under “Preferred Stock”). Between October and December 2018, the Company issued 177,900 shares of common stock as the result of the exercise of warrants resulting in cash proceeds of $192,132. On February 14, 2017, The NASDAQ Stock Market LLC informed the Company that it had approved the listing of the Company’s common stock on The NASDAQ Capital Market, effective as of February 15, 2017. The Company’s common stock ceased trading on the OTCQB on February 15, 2017, and on such date the common stock commenced trading on The NASDAQ Capital Market under the ticker symbol “SGLB”. In October 2017, pursuant to an advisory agreement with Dawson James Securities, the Company issued to Dawson James a total of 141,000 shares of the Company’s common stock in exchange for the surrender by Dawson James of its Unit Purchase Option to acquire up to 70,500 Units that was issued by the Company in the 2017 public offering. In November 2017, the Company issued 56,000 shares of common stock as the result of the exercise of warrants resulting in cash proceeds of $112,000. In December 2017, the Company issued 204,578 shares of common stock as the result of a conversion of the $400,000 principal balance of Notes Payable and $8,556 of accrued interest. In 2017, the Company issued 40,934 shares of common stock to directors at an average value of $2.09 per share, or $85,408. Also in 2017, 7,500 shares previously issued to a director and 750 shares previously issued to an employee, with a combined carrying value of $9,830, were forfeited. Deferred Compensation In previous years and 2018, the Company issued to various employees, directors, and contractors shares of the Company’s common stock, subject to restrictions, pursuant to the 2013 Equity Incentive Plan (the “2013 Plan”). Such shares were valued at the fair value at the date of issue. The fair value was expensed as compensation over the vesting period and recorded as a reduction of stockholders’ equity. During 2018 and 2017, $277,515 and $209,300, respectively, of the unvested compensation cost related to these issues was recognized. As of December 31, 2018 and 2017, the balance of unvested compensation to be recognized was $21,355 and $31,576, respectively, and is recorded as prepaid stock compensation as of those dates. Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, $0.001 par value. No shares of preferred stock were issued and outstanding at December 31, 2018 or 2017. In April 2018, the Company issued 1,000 shares of the Company’s newly-created non-voting Series B Convertible Preferred Stock, which were convertible into 1,000,000 shares of common stock and warrants to purchase an aggregate of 750,000 shares of the Company’s common stock, for an aggregate purchase price of $1,000,000. The warrants have an initial exercise price of $1.47 per share, the closing price of the Company’s common stock reported on The NASDAQ Capital Market on April 6, 2018, subject to adjustment in certain circumstances. The net proceeds to the Company were approximately $877,500 after commissions and other offering expenses. The Company also issued to Dawson James Securities, Inc., its placement agent in the foregoing private placement, warrants to purchase up to 140,000 shares of common stock, at an exercise price of $1.47 per share, as compensation. In June 2018, as part of the public offering described in Note 1, the Company issued 350 shares of the Company’s newly-created non-voting Series C Convertible Preferred Stock, which were convertible into 350,000 shares of common stock, and warrants to purchase an aggregate of 105,000 shares of the Company’s common stock. The warrants have an initial exercise price of $1.08 per share, 11% above the closing price of the Company’s common stock reported on The NASDAQ Capital Market on June 26, 2018, subject to adjustment in certain circumstances. Stock Options In October 2017, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by 375,000 shares of our common stock to a total of 750,000 shares. As of December 31, 2017, an aggregate of 750 shares and 450,062 shares of common stock were reserved for issuance under the 2011 Plan and the 2013 Plan, respectively. In October 2018, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by 900,000 shares of our common stock to a total of 1,650,000 shares. As of December 31, 2018, an aggregate of 750 shares and 508,885 shares of common stock were reserved for issuance under the 2011 Plan and the 2013 Plan, respectively. During 2018, the Company granted a total of 534,329 options to 18 employees and 1 consultant with vesting periods ranging from immediately/upon issue to 4 years beginning February 2018. In 2018, 415,492 options vested and $868,015 of compensation cost was recognized during the year. As of December 31, 2018, there were options to purchase 826,267 shares issued and outstanding under the 2013 Plan. Of this amount, there are vested options exercisable for 500,980 shares of common stock. No options were exercised during the year ended December 31, 2018. During 2017, the Company granted a total of 213,750 options to 5 employees with vesting periods ranging from 18 months to 4 years beginning May 2017. In 2017, 82,676 options vested, and $510,496 of compensation cost was recognized during the year. As of December 31, 2017, there were options to purchase 299,938 shares issued and outstanding under the 2013 Plan. Of this amount, there are vested options exercisable for 85,614 shares of common stock. As of December 31, 2017, the Company had 200,419 shares reserved for future grant under its plans and there were no options exercised during the year ended December 31, 2017. The Company generally grants stock options to employees and directors at exercise prices equal to the fair market value of the Company’s stock on the dates of grant. Stock options are typically granted throughout the year and generally vest over four years of service and expire ten years from the date of the award, unless otherwise specified. The Company recognizes compensation expense for the fair value of the stock options over the requisite service period for each stock option award. Total share-based compensation expense included in the consolidated statements of operations for the years ended December 31, 2018 and 2017 is $1,145,530, of which $868,015 is related to stock options, and $719,796, of which $510,496 is related to stock options, respectively. There was no capitalized share-based compensation cost as of December 31, 2018 and 2017, and there were no recognized tax benefits during the years ended December 31, 2018 and 2017. To estimate the value of an award, the Company uses the Black-Scholes option-pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. The forfeiture rate also impacts the amount of aggregate compensation. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life, volatility and forfeiture rate are derived primarily from the Company’s historical data, the risk-free rate is based on the yield available on U.S. Treasury constant maturity rates with similar terms to the expected term of the stock option awards. The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2018 and 2017: Assumptions: 2018 2017 Dividend yield 0.00 0.00 Risk-free interest rate 2.68-3.10 % 1.91-2.45 % Expected volatility 104.9-137.3 % 115.9-139 % Expected life (in years) 5-10 5-10 Option activity for the year ended December 31, 2018 and 2017 was as follows: Weighted Average Weighted Average Exercise Remaining Aggregate Price Contractual Intrinsic Options ($) Life (Yrs.) Value ($) Options outstanding at December 31, 2016 101,188 8.39 9.29 - Granted 213,750 2.95 7.72 16,600 Exercised - - - - Forfeited or cancelled (15,000 ) 5.43 - - Options outstanding at December 31, 2017 299,938 4.57 7.33 16,600 Granted 534,329 1.45 6.58 - Exercised - - - - Forfeited or cancelled (8,000 ) 4.59 - - Options outstanding at December 31, 2018 826,267 2.49 6.47 60,090 Options expected to vest in the future as of December 31, 2018 325,287 2.54 6.84 28,332 Options exercisable at December 31, 2018 500,980 2.42 6.23 31,758 Options vested, exercisable, and options expected to vest at December 31, 2018 826,267 2.49 6.47 60,090 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price currently below the $1.50 closing price of our Common Stock on December 31, 2018. Sixteen of the 2018 option grants have an exercise price currently below $1.50. At December 31, 2018, there was $312,655 of unrecognized share-based compensation expense related to unvested share options with a weighted average remaining recognition period of 6.47 years. Warrants At December 31, 2018, the Company had outstanding warrants to purchase a total of 3,050,600 shares of common stock; 1,621,500 warrants at an exercise price of $4.00 per share, which if not exercised, will expire on February 21, 2022, 890,000 warrants at an exercise price of $1.47 per share, which if not exercised, will expire on October 07, 2023, and 539,100 warrants at an exercise price of $1.08 per share, which if not exercised, will expire on June 26, 2023. Warrant activity for the year ended December 31, 2018 and 2017 was as follows: Weighted Average Weighted Average Exercise Remaining Price Contractual Warrants ($) Life (Yrs.) Warrants outstanding at December 31, 2016 80,000 2.00 2.79 Granted 1,621,500 4.00 1.79 Exercised (56,000 ) 2.00 - Forfeited or cancelled - - - Options outstanding at December 31, 2017 1,645,500 3.97 4.11 Granted 1,607,000 1.30 4.64 Exercised (201,900) 1.19 - Forfeited or cancelled - - - Options outstanding at December 31, 2018 3,050,600 2.75 3.86 On May 31, 2018, 24,000 warrants with an exercise price of $2.00 were exercised in a cashless exchange transaction resulting in the issuance of 4,800 shares of the Company’s common stock. Between October 18, 2018 and December 17, 2018, 177,900 warrants with an exercise price of $1.08 were exercised resulting in the issuance of 177,900 shares of common stock.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8 – Income Taxes The Company accounts for income taxes in accordance with ASC Topic No. 740. This standard requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards. Income tax returns open for examination by the Internal Revenue Service consist of tax years ended December 31, 2015 through 2017. The Company has available at December 31, 2018, unused operating loss carryforwards of approximately $10,027,000, which may be applied against future taxable income and which expire in various years through 2038. However, if certain substantial changes in the Company’s ownership should occur, there could be an annual limitation on the amount of net operating loss carryforward which can be utilized. The amount of and ultimate realization of the benefits from the operating loss carryforwards for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company and other future events, the effects of which cannot be determined. Because of the uncertainty surrounding the realization of the loss carryforwards, the Company has established a valuation allowance equal to the tax effect of the loss carryforwards and other temporary differences of approximately $2,123,700 and $2,929,900 at December 31, 2018 and 2017, respectively, and, therefore, no deferred tax asset has been recognized for the loss carryforwards. Deferred tax assets are comprised of the following: 2018 2017 Deferred tax assets: NOL carryover $ 2,105,600 $ 2,929,900 Depreciation 18,100 - Valuation allowance (2,123,700 ) (2,929,900 ) Net deferred tax asset $ - $ - The reconciliation of the provision for income taxes computed at the U.S. federal statutory tax rate (21%) to the Company’s effective tax rate for the period ended December 31, 2018 and 2017 is as follows: 2018 2017 Book Loss $ (1,170,600 ) $ (1,556,355 ) Depreciation 13,400 - Meals & Entertainment 2,600 3,200 Stock Compensation 242,730 - Loss on Asset Disposal 7,714 Change in valuation allowance 904,156 1,553,200 Provision for Income Taxes $ - $ -

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Loss Per Share	NOTE 9 – Loss Per Share The following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended December 31, 2018 and 2017: Year Ended December 31 2018 2017 Loss from continuing Operations available to Common stockholders (numerator) $ (5,574,163 ) $ (4,424,503 ) Weighted average number of common shares Outstanding used in loss per share during the Period (denominator) 6,898,047 4,403,479 Dilutive loss per share was not presented as the Company’s outstanding warrants, stock options and note conversion features common equivalent shares for the periods presented would have had an anti-dilutive effect. At December 31, 2018, the Company had outstanding 3,050,600 warrants which could be converted to 3,050,600 shares of common stock, a $50,000 note payable convertible into 25,000 shares of common stock, and 826,267 stock options exercisable for 826,267 shares of common stock resulting in a potential total additional 3,901,867 common stock shares outstanding in the future. At December 31, 2017 the Company had outstanding 1,434,000 warrants which could be converted to 1,434,000 shares of common stock, a $100,000 note payable convertible into 50,000 shares of common stock, and 299,938 stock options exercisable for 299,938 shares of common stock resulting in a potential total additional 1,783,938 common stock shares outstanding in the future.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 – Commitments and Contingencies Operating Leases

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2018
Risks and Uncertainties [Abstract]
Concentrations	NOTE 10 – Concentrations Revenues Customer 2018 2017 A 23.34 % 0.77 % B 12.87 % - C 12.62 % - D 12.18 % 28.75 % E 0.94 % 19.83 % F 0.21 % 14.23 % G - 12.85 % Accounts Receivable Customer 2018 2017 A 64.43 % - B 17.01 % - C 12.11 % - D - 44.34 % E - 23.21 % F - 21.33 %

Joint Venture

Joint Venture	12 Months Ended
	Dec. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture	NOTE 11 - Joint Venture In July 2015, we entered into a joint venture agreement with Arete Innovative Solutions LLC (“Arete”). The Joint Venture was not consolidated, but rather was accounted for on the equity method of recording investments. There were no operating activities during the fiscal 2017 and net operations resulted in a loss on the investment of $105 in fiscal 2016. The Company and Arete agreed in 2017 to terminate the Joint Venture and are in the process of paying final costs. The remaining cash asset of the company will be distributed to the former partners in 2019.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2018
Defined Contribution Plan
Defined Contribution Plan	Note 12 - Defined Contribution Plan In 2014, the Company adopted a qualified 401(K) plan (“the Plan”), in which all employees over the age of 21 may participate. The Company has elected to match 100% of each participant’s contribution up to 3% of salary, and 50% of the next 2% of salary contributed. The Company may also elect, on an annual basis, to make a discretionary contribution to the plan. Company matches and discretionary contributions vest to participant accounts as follows: 20% after two years of service, and 20% per year thereafter until the participant reaches 6 years of service, at which time, employer contributions vest 100%. The costs of matching contributions were $51,415 in 2018 and $33,725 in 2017.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 13 – Related Party Transactions On September 10, 2018 Mr. Cola submitted notice to the Company of his resignation effective October 10, 2018. As a result, Mr. Cola was entitled to receive the severance and other benefits described under Section 10 of the Employment Agreement. As of October 10, 2018, the Company determined the total cost of the continuation to be $224,818 and recognized that amount as severance expense and a severance obligation. Through December 31, 2018, the Company has paid out $40,862 of the obligation and has a remaining obligation of $183,956 that is scheduled to be paid out in nineteen semi-monthly installments of $9,367 through October 1, 2019 and a final $5,983 installment on October 15, 2019. Effective October 10, 2018 the Company entered into a one-year Consulting Agreement with Mr. Cola as an independent contractor to provide non-exclusive consulting services to the Company on as an-needed basis at the rate of $250 per hour. The agreement provides that as long as the Consulting Agreement remains in effect, the stock options of the Company held by Mr. Cola shall remain exercisable and continue to vest in accordance with the terms of the Consultants existing stock options agreements of the Company. Through December 31, 2018, Mr. Cola has $2,678 in payment for services rendered under the Consulting Agreement.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 14 – Subsequent Events In January 2019, Sigma issued each of its four non-employee directors 50,000 shares of common stock, under the 2013 Equity Incentive Plan, with such shares to vest ratably over four quarterly installments, subject in each case to such director’s continuing service as a director. In January 2019, the Company granted to twelve employees options under the 2013 Equity Incentive Plan options to purchase an aggregate of up to 99,376 shares of common stock, with each option having an exercise price equal to $1.50 per share, which was the closing market price of the company’s stock on December 31, 2018, (i.e., the trading day immediately preceding the date of grant) and vesting ratably over four years on each anniversary date of the grant subject in each case to the employee’s continuing employment with the Company. In January 2019, the Company granted to our Vice-President of Business Development a fully vested option to purchase up to 11,832 shares of common with an exercise price of $2.02, which was the closing price of the Company’s stock on the date of grant, in exchange for the cancellation of his accrued and unpaid vacation balance as of December 31, 2018. Also in January 2019, the Company issued 90,831 shares of common stock upon the cashless exercise of Unit Purchase Options issued in our June 2018 public offering. In January and February 2019, the Company issued a total of 67,830 shares of common stock upon the exercise of 67,830 warrants having an exercise price of $1.08 resulting in gross cash proceeds of $73,256. In the first quarter of 2019, the Company granted our CEO and President three options (the “Options”) to purchase up to 22,916 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment arrangement. The Options have an exercise price per share equal to $1.50, $1.9262, and $2.04, respectively, and each is fully vested. On March 9, 2019, the Company issued to our Vice President of Business Development 1,500 shares of common stock, which vested immediately, in connection with the satisfaction of a performance milestone. On March 15, 2019, the Company closed a public offering of equity securities in which it issued 1,400,800 shares of common stock and warrants to purchase a total of 420,240 shares of common stock resulting in net proceeds of approximately $1,679,230, after deducting placement agent commissions and other offering expenses payable by the Company. During the first quarter of 2019, the Company received notice of the issuance of two new patents: Patent No. 10207489 “Systems and Methods for Additive Manufacturing Operations” and Patent No. 10226817, Material Qualification System and Methodology”.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Nature of Business	Nature of Business
Basis of Presentation	Basis of Presentation
Reclassification	Reclassification
Continuing Operations	Continuing Operations – As a result, the Company currently has sufficient cash and working capital to fund operations through the end of the third quarter of 2019 and is anticipating that Phase II proof of concept contracts may be closed in the second and third quarter of fiscal 2019 generating additional cash flow in the near term. In addition, the Company has access to public and private markets from which to derive additional financing to sustain operations beyond that term, if required.
Loss Per Share	Loss Per Share –
Property and Equipment	Property and Equipment – In accordance with its policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis. This review in 2017 indicated that the actual useful life of the leasehold improvements the Company made to the leased facilities at 3900 Paseo del Sol, Santa Fe, New Mexico in 2014, is less than the fifteen-year estimated useful life that was being used for depreciation purposes in the Company’s financial statements. As a result, effective January 1, 2017, the Company changed the estimated useful life of these improvements to seven years. The effect of this change in estimate was to increase 2017 depreciation expense by $12,291.
Fair Value of Financial Instruments	Fair Value of Financial Instruments . ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying amounts reported in the balance sheets for the cash and cash equivalents, prepaid stock compensation, receivables, accounts payable, and accrued liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. Although the Company had no other financial instruments requiring fair value disclosures, during 2017, the company wrote off a $93,206 fair value amount of a derivative liability balance from December 31, 2016. The derivative liability was the result of the original $1 million of Notes, and the 80,000 warrants, that were issued in October 2016, both of which contain anti-dilution provisions in the event the Company engages in specified transactions which occurred in February 2017. As a result, the instruments no longer required derivative treatment and were written off in February 2017. The following table presents a reconciliation of the derivative liability measured at fair value on a recurring basis using significant unobservable input (Level 3): Notes & Warrants Balance December 31, 2016 $ 93,206 Change in fair value 186,908 Write-off of derivative (280,114 ) Balance December 31, 2017 $ - During 2018 there were no instruments measured at fair value on a recurring basis.
Income Taxes	Income Taxes – The Company has no tax positions at December 31, 2018 and 2017 for which the ultimate deductibility is highly uncertain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the years ended December 31, 2018 and 2017, the Company recognized no interest and penalties. All tax years starting with 2015 are open for examination.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
Long-Lived and Intangible Assets	Long-Lived and Intangible Assets
Cash Equivalents	Cash Equivalents
Concentration of Credit Risk	Concentration of Credit Risk -
Stock Based Compensation	Stock Based Compensation Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No. 505, “Equity Based Payments to Non-Employees.” In general, the measurement date is either (a) when a performance commitment, as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.
Amortization	Amortization
Accounting Estimates	Accounting Estimates
Revenue Recognition	Revenue Recognition – Revenue from Contracts with Customers We adopted this new revenue recognition standard along with is related amendments on January 1, 2018 and have updated our accounting policy for revenue recognition. As expected, at our current level of revenue, the adoption of this new standard did not impact our financial position or results of operations operating cash flows. In general, we determine revenue recognition by: (1) identifying the contract, or contracts, with our customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to performance obligations in the contract; and (5) recognizing revenue when, or as, we satisfy performance obligations by transferring the promised goods or services.
Deferred Stock Offering Costs	Deferred Stock Offering Costs
Inventory	Inventory
Research and Development	Research and Development

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Derivative Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Input	The following table presents a reconciliation of the derivative liability measured at fair value on a recurring basis using significant unobservable input (Level 3): Notes & Warrants Balance December 31, 2016 $ 93,206 Change in fair value 186,908 Write-off of derivative (280,114 ) Balance December 31, 2017 $ -

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	At December 31, 2018 and December 31, 2017, the Company’s inventory was comprised of: December 31 2018 December 31, 2017 Raw Materials $ 168,623 $ 127,076 Work in Process 46,688 251 Finished Goods 24,775 65,378 Total Inventory $ 240,086 $ 192,705

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The following is a summary of property and equipment, purchased, used and depreciated over a five year period, less accumulated depreciation, as of December 31, 2018 and 2017: Year Ended December 31, 2018 2017 Property and Equipment $ 1,074,888 $ 1,027,966 Less: Accumulated Depreciation (796,944 ) (616,322 ) Net Property and Equipment $ 277,944 $ 411,643

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Definite-life Intangible Assets and Accumulated Amortization	The following is a summary of definite-life intangible assets less accumulated amortization as of December 31, 2018 and 2017, respectively: Year Ended December 31, 2018 2017 Provisional Patent Applications $ 366,353 $ 254,570 Patents 47,073 59,701 Less: Accumulated Amortization (8,448 ) (19,875 ) Net Intangible Assets $ 404,978 $ 294,396
Schedule of Aggregate Amortization Expense	The estimated aggregate amortization expense for each of the succeeding years ending December 31 is as follows: 2019 $ 2,769 2020 2,769 2021 2,769 2022 2,769 Thereafter 27,549 $ 38,625

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2018 and 2017: Assumptions: 2018 2017 Dividend yield 0.00 0.00 Risk-free interest rate 2.68-3.10 % 1.91-2.45 % Expected volatility 104.9-137.3 % 115.9-139 % Expected life (in years) 5-10 5-10
Schedule of Stock Option Activity	Option activity for the year ended December 31, 2018 and 2017 was as follows: Weighted Average Weighted Average Exercise Remaining Aggregate Price Contractual Intrinsic Options ($) Life (Yrs.) Value ($) Options outstanding at December 31, 2016 101,188 8.39 9.29 - Granted 213,750 2.95 7.72 16,600 Exercised - - - - Forfeited or cancelled (15,000 ) 5.43 - - Options outstanding at December 31, 2017 299,938 4.57 7.33 16,600 Granted 534,329 1.45 6.58 - Exercised - - - - Forfeited or cancelled (8,000 ) 4.59 - - Options outstanding at December 31, 2018 826,267 2.49 6.47 60,090 Options expected to vest in the future as of December 31, 2018 325,287 2.54 6.84 28,332 Options exercisable at December 31, 2018 500,980 2.42 6.23 31,758 Options vested, exercisable, and options expected to vest at December 31, 2018 826,267 2.49 6.47 60,090
Summary of Warrant Activity	Warrant activity for the year ended December 31, 2018 and 2017 was as follows: Weighted Average Weighted Average Exercise Remaining Price Contractual Warrants ($) Life (Yrs.) Warrants outstanding at December 31, 2016 80,000 2.00 2.79 Granted 1,621,500 4.00 1.79 Exercised (56,000 ) 2.00 - Forfeited or cancelled - - - Options outstanding at December 31, 2017 1,645,500 3.97 4.11 Granted 1,607,000 1.30 4.64 Exercised (201,900) 1.19 - Forfeited or cancelled - - - Options outstanding at December 31, 2018 3,050,600 2.75 3.86

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred tax assets are comprised of the following: 2018 2017 Deferred tax assets: NOL carryover $ 2,105,600 $ 2,929,900 Depreciation 18,100 - Valuation allowance (2,123,700 ) (2,929,900 ) Net deferred tax asset $ - $ -
Schedule of Reconciliation of the Provision for Income Taxes	The reconciliation of the provision for income taxes computed at the U.S. federal statutory tax rate (21%) to the Company’s effective tax rate for the period ended December 31, 2018 and 2017 is as follows: 2018 2017 Book Loss $ (1,170,600 ) $ (1,556,355 ) Depreciation 13,400 - Meals & Entertainment 2,600 3,200 Stock Compensation 242,730 - Loss on Asset Disposal 7,714 Change in valuation allowance 904,156 1,553,200 Provision for Income Taxes $ - $ -

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended December 31, 2018 and 2017: Year Ended December 31 2018 2017 Loss from continuing Operations available to Common stockholders (numerator) $ (5,574,163 ) $ (4,424,503 ) Weighted average number of common shares Outstanding used in loss per share during the Period (denominator) 6,898,047 4,403,479

Concentrations (Tables)

Concentrations (Tables)	12 Months Ended
	Dec. 31, 2018
Risks and Uncertainties [Abstract]
Schedule of Concentration of Risks	The change in the composition of customers between the two years resulted primarily from the change of focus from sales to R&D customers to Proof of Concept sales to customers preparing to initiate commercial production. Customer 2018 2017 A 23.34 % 0.77 % B 12.87 % - C 12.62 % - D 12.18 % 28.75 % E 0.94 % 19.83 % F 0.21 % 14.23 % G - 12.85 % Customer 2018 2017 A 64.43 % - B 17.01 % - C 12.11 % - D - 44.34 % E - 23.21 % F - 21.33 %

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Feb. 21, 2017	Dec. 31, 2018	Oct. 31, 2018	Jun. 30, 2018	May 31, 2018	May 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Mar. 28, 2018	Dec. 31, 2016	Oct. 31, 2016
Issunace cost									$ 153,013
Proceeds form public offering of equity securities	$ 5,097,000			$ 2,068,900			$ 877,500
Cash balance		$ 1,279,782							$ 1,279,782	$ 1,515,674		$ 398,391
Number of warrants issued		3,050,600		717,000					3,050,600	1,434,000			80,000
Number of shares issued		177,900	177,900	2,040,000	1,000,000	29,800			3,901,867	1,783,938
Convertible note payable		$ 50,000							$ 50,000	$ 100,000
Estimated useful life of property and equipment									5 years
Increase in depreciation expense										12,291
Write off fair value amount of derivative liability										93,206
Debt instrument face value		1,000,000							$ 1,000,000
Income tax interest and penalties
Allowance for doubtful accounts receivable
Asset impairment charges
Finite-lived intangible asset, useful life									17 years
Inventory		$ 240,086							$ 240,086	192,705
Research and development costs									$ 493,410	$ 302,043
Dental Patents [Member]
Write off intangible asset								$ 50,255
Leasehold Improvements [Member]
Estimated useful life of property and equipment									7 years
Leasehold Improvements [Member] | Maximum [Member]
Estimated useful life of property and equipment									15 years
Stock Option [Member]
Number of shares issued									826,267	299,938
March 15, 2019 [Member]
Proceeds form public offering of equity securities									$ 1,679,230
Morf3D, Inc. [Member]
Full payment received from related party											$ 535,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Input (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Change in fair value		$ 186,908
Write-off of derivative		(280,114)
Derivative Liability Notes and Warrants [Member]
Balance December 31, 2016		93,206
Change in fair value		186,908
Write-off of derivative		(280,114)
Balance December 31, 2017

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)	Jul. 02, 2018	Jun. 15, 2018	Jun. 07, 2018	Jun. 06, 2018	Apr. 27, 2018	Mar. 17, 2018	May 01, 2017	Oct. 31, 2018	Dec. 31, 2018	Mar. 27, 2017
Debt principal amount									$ 1,000,000
Debt maturity period								Apr. 18, 2019
Secured Convertible Promissory Note [Member]
Interest rate							10.00%
Promissory Note [Member]
Debt principal amount									117,803
Interest rate					50.00%
Debt maturity period				Aug. 1, 2018	Jun. 1, 2018
Exchange for cash payment	$ 8,000		$ 10,000	$ 10,000	$ 5,000
Proceeds from notes receivable				$ 10,000
Debt accumulated interest									$ 4,110
Jaguar Precision Machine, LLC [Member] | Secured Convertible Promissory Note [Member]
Debt principal amount							$ 250,000
Interest rate							7.00%
Debt maturity period							May 1, 2018
Jaguar Precision Machine, LLC [Member] | Promissory Note [Member]
Debt principal amount		$ 132,197
Proceeds from notes receivable		150,000
Debt accumulated interest		$ 17,803
Morf3D, Inc. [Member] | Secured Convertible Promissory Note [Member]
Debt principal amount						$ 500,000				$ 500,000
Interest rate										7.00%
Debt accumulated interest						$ 35,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw Materials	$ 168,623	$ 127,076
Work in Process	46,688	251
Finished Goods	24,775	65,378
Total Inventory	$ 240,086	$ 192,705

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 190,280	$ 193,892

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	$ 1,074,888	$ 1,027,966
Less: Accumulated Depreciation	(796,944)	(616,322)
Net Property and Equipment	$ 277,944	$ 411,643

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jun. 19, 2018
Accumulated amortization of patent	$ (8,448)	$ (19,875)
Patent cost	404,978	294,396	$ 25,021
Amortization expense	2,094	$ 3,051
Patent [Member]
Wrote off of patent cost	37,649
Accumulated amortization of patent	13,522
Provisional patent application cost	$ 12,606

Intangible Assets - Summary of

Intangible Assets - Summary of Definite-life Intangible Assets and Accumulated Amortization (Details) - USD ($)	Dec. 31, 2018	Jun. 19, 2018	Dec. 31, 2017
Less: Accumulated Amortization	$ (8,448)		$ (19,875)
Net Intangible Assets	404,978	$ 25,021	294,396
Provisional Patent Applications [Member]
Intangible Assets	366,353		254,570
Patents [Member]
Intangible Assets	$ 47,073		$ 59,701

Intangible Assets - Schedule of

Intangible Assets - Schedule of Aggregate Amortization Expense (Details) - USD ($)	Dec. 31, 2018	Jun. 19, 2018	Dec. 31, 2017
Intangible asset and amortization expense	$ 404,978	$ 25,021	$ 294,396
Intangible Assets [Member]
2019	2,769
2020	2,769
2021	2,769
2022	2,769
Thereafter	27,549
Intangible asset and amortization expense	$ 38,625

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	May 31, 2018	Oct. 17, 2016	Dec. 31, 2018	Oct. 31, 2018	Jun. 30, 2018	May 31, 2018	May 31, 2018	Apr. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Oct. 18, 2018
Conversion description and warrants description		On September 29, 2017, the Company entered into amendments (the "Amendments") to the October 17, 2016 Secured Convertible Promissory Notes and Warrants to purchase shares of the Company's common stock, pursuant to which, among other things set forth in the Amendments, (1) the exercise price of the Warrants was reduced from $4.13 per share to $2.00 per share, and (2) the conversion price of the Notes was reduced from $4.13 per share to $2.00 per share. Under the Amendments, we paid the Holders an aggregate amount equal to $500,000 (representing 50% of the outstanding principal balance of the Notes) plus all accrued interest on the Notes. In consideration of the foregoing, the Holders agreed to, among other things, extend the payment date of the remaining 50% of the outstanding principal balance of the Notes from October 17, 2017 to the earlier of May 18, 2018 or the closing of our next underwritten public offering of securities in which we raise gross proceeds of at least $3,000,000 (should we elect to commence and close such an offering of securities).
Exercise price of warrants					$ 1.08
Payments of debt		$ 500,000
Gross proceeds note payable		$ 3,000,000
Note payable, principal amount	$ 50,000					$ 50,000	$ 50,000
Accrued interest				$ 3,444								$ 3,444
Common stock issued during period			177,900	177,900	2,040,000	1,000,000	29,800			3,901,867	1,783,938
Warrant exercised	24,000					24,000	24,000
Debt maturity date				Apr. 18, 2019
Payment for public offering of equity securities										$ 443,700	$ 750,664
Holders [Member]
Exercise price of warrants									$ 2		$ 2
Note payable, principal amount									$ 500,000		$ 500,000
Convertible debt			$ 50,000						400,000	50,000	400,000
Accrued interest			$ 1,028					$ 8,761	$ 8,556	$ 1,028	$ 8,556
Common stock issued during period	4,800					25,000			204,278
Warrant exercised									56,000		56,000
Remaining payment of debt								$ 100,000
Debt maturity date								Oct. 18, 2018
Payment for public offering of equity securities								$ 3,000,000
Value of shares converted						$ 50,000
Number of cashless exercise warrant shares	24,000					24,000	24,000
Maximum [Member]
Exercise price of warrants		$ 4.13
Conversion price per share		4.13
Minimum [Member]
Exercise price of warrants		2
Conversion price per share		$ 2

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	May 31, 2018	Feb. 21, 2017	Feb. 15, 2017	Dec. 31, 2018	Oct. 31, 2018	Jun. 30, 2018	May 31, 2018	May 31, 2018	Apr. 30, 2018	Dec. 31, 2017	Nov. 30, 2017	Oct. 31, 2017	Dec. 17, 2018	Dec. 31, 2018	Dec. 31, 2017	Oct. 18, 2018	Aug. 31, 2018	Mar. 05, 2018	Oct. 31, 2016	Oct. 17, 2016
Reverse stock split			1-for-2 basis
Common stock, shares authorized				22,500,000						22,500,000				22,500,000	22,500,000	22,500,000		15,000,000
Common stock issued during period				177,900	177,900	2,040,000	1,000,000	29,800						3,901,867	1,783,938
Notes payable principal balance	$ 50,000						$ 50,000	$ 50,000
Warrant exercised	24,000						24,000	24,000
Warrants to purchase shares of common stock				3,050,600		717,000				1,434,000				3,050,600	1,434,000				80,000
Warrants exercise price						$ 1.08
Proceeds from public offering		$ 5,097,000				$ 2,068,900			$ 877,500
Proceeds from issuance of common Stock and warrants				$ 192,132	$ 192,132									$ 2,040,100	$ 5,823,300
Accrued interest					$ 3,444											$ 3,444
Unvested compensation cost				277,515						$ 209,300				277,515	209,300
Unvested prepaid stock compensation				$ 21,355						$ 31,576				$ 21,355	$ 31,576
Preferred stock, shares authorized				10,000,000						10,000,000				10,000,000	10,000,000
Preferred stock, par value				$ 0.001						$ 0.001				$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Number of shares granted														534,329	213,750
Stock options compensation cost														$ 312,655
Number of option vested, exercisable				826,267						299,938				826,267	299,938
Number of options exercised
Share based compensation														$ 1,145,530	$ 719,796
Option term														6 years 5 months 20 days	7 years 3 months 29 days
Options exercise price														$ 1.50
Minimum [Member]
Warrants exercise price																				$ 2
Maximum [Member]
Warrants exercise price																				$ 4.13
2013 Stock Option Plan [Member]
Common stock issued during period					1,650,000							750,000
Common stock shares reserved for issaunce					900,000							375,000
2011 Stock Option Plan 1 [Member]
Common stock shares reserved for issaunce										450,062					450,062
Number of option vested, exercisable										85,614					85,614
2013 Stock Option Plan [Member]
Common stock issued during period														750	750,000
Common stock shares reserved for issaunce				508,885						450,062				508,885	450,062
Stock options purchased														826,267
Number of option vested, exercisable				500,980										500,980
Number of options exercised
2011 Stock Option Plan [Member]
Common stock issued during period														750
Common stock shares reserved for issaunce				508,885										508,885
Stock options purchased															299,938
Number of options exercised
2011 Stock Option Plan 2 [Member]
Common stock shares reserved for issaunce										200,419					200,419
Private Placement [Member]
Warrants to purchase shares of common stock									140,000
Warrants exercise price									$ 1.47
Common Stock [Member]
Conversion of preferred stock					350,000												350,000
Aggregation of purchase price									$ 1,000,000
Number of options exercised															141,000
Warrant [Member]
Warrant exercised				3,050,600						1,434,000				3,050,600	1,434,000
Warrants to purchase shares of common stock	24,000					105,000	24,000	24,000	750,000
Warrants exercise price	$ 2					$ 1.08	$ 2	$ 2	$ 1.47
Warrant One [Member]
Warrants to purchase shares of common stock				3,050,600										3,050,600
Warrant Two [Member]
Warrants to purchase shares of common stock				1,621,500										1,621,500
Warrants exercise price				$ 4										$ 4
Warrants expiration														Feb. 21, 2022
Warrant Three [Member]
Warrants to purchase shares of common stock				890,000										890,000
Warrants exercise price				$ 1.47										$ 1.47
Warrants expiration														Oct. 7, 2023
Warrant Four [Member]
Warrants to purchase shares of common stock				539,100										539,100
Warrants exercise price				$ 1.08										$ 1.08
Warrants expiration														Jun. 26, 2023
Warrants [Member]
Common stock issued during period	4,800												177,900
Warrants to purchase shares of common stock													177,900
Warrants exercise price													$ 1.08
Dawson James Securities, Inc [Member]
Common stock issued during period						191,200
Share price per share						$ 1.25
Warrants to purchase shares of common stock						57,360
Warrants exercise price						$ 1.08
Option to acquire shares						191,200
Series B Convertible Preferred Stock [Member]
Conversion of stock, shares converted						350	1,000
Series C Convertible Preferred Stock and Warrants [Member]
Conversion of preferred stock					350												350
Series B Convertible Preferred [Member]
Common stock issued during period									1,000
Conversion of stock, shares converted									1,000,000
Series C Convertible Preferred [Member]
Common stock issued during period						350
Conversion of stock, shares converted						350,000
Directors [Member]
Common stock issued during period														200,000	40,934
Share price per share				$ 1.28						$ 2.09				$ 1.28	$ 2.09
Common stock issued during period, value														$ 256,264	$ 85,408
Stock issued during period of forfeited															9,830
Dawson James [Member]
Common stock issued during period										204,578	56,000	141,000
Notes payable principal balance										$ 400,000					400,000
Option to acquire shares												70,500
Proceeds from issuance of common Stock and warrants											$ 112,000
Accrued interest										$ 8,556					$ 8,556
Directors One [Member]
Common stock issued during period															7,500
Employee [Member]
Common stock issued during period															750
18 Employees and 1 Consultant [Member]
Number of shares granted														534,329
Vesting period														4 years
Number of shares vested														415,492
Stock options compensation cost														$ 868,015
5 Employees [Member]
Number of shares granted															213,750
Number of shares vested															82,676
Stock options compensation cost															$ 510,496
5 Employees [Member] | Minimum [Member]
Vesting period															18 months
5 Employees [Member] | Maximum [Member]
Vesting period															4 years

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Dividend yield	0.00%	0.00%
Risk-free interest rate, minimum	2.68%	1.91%
Risk-free interest rate, maximum	3.10%	2.45%
Expected volatility, minimum	104.90%	115.90%
Expected volatility, maximum	137.30%	139.00%
Minimum [Member]
Expected life (in years)	5 years	5 years
Maximum [Member]
Expected life (in years)	10 years	10 years

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Number of Options Outstanding, Beginning Balance	299,938	101,188
Number of Options Granted	534,329	213,750
Number of Options Exercised
Number of Options Forfeited or cancelled	(8,000)	(15,000)
Number of Options Outstanding Ending Balance	826,267	299,938
Number of Option Expected to Vest in the Future Ending Balance	325,287
Number of Options Exercisable	500,980
Number of Option Vested, Exercisable and Options Expected to Vest Ending Balance	826,267	299,938
Weighted Average Exercise Price Outstanding Beginning Balance	$ 4.57	$ 8.39
Weighted Average Exercise Price Granted	1.45	2.95
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Forfeited or cancelled	4.59	5.43
Weighted Average Exercise Price Outstanding	2.49	$ 4.57
Weighted Average Exercise Price Expected to Vest	2.54
Weighted Average Exercise Price Exercisable	2.42
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 2.49
Weighted Average Remaining Contractual Life Outstanding Beginning	7 years 3 months 29 days	9 years 3 months 15 days
Weighted Average Remaining Contractual Life Granted	6 years 6 months 29 days	7 years 8 months 19 days
Weighted Average Remaining Contractual Life Outstanding	6 years 5 months 20 days	7 years 3 months 29 days
Weighted Average Remaining Contractual Life Expected to Vest	6 years 10 months 3 days
Weighted Average Remaining Contractual Life Exercisable	6 years 2 months 23 days
Weighted Average Remaining Contractual Life Vested, Exercisable and Options Expected to Vest	6 years 5 months 20 days
Aggregate Intrinsic Value, Outstanding	$ 16,600
Aggregate Intrinsic Value, Granted		$ 16,600
Aggregate Intrinsic Value, Outstanding	$ 60,090	$ 16,600
Aggregate Intrinsic Value Options expected to vest in the future	28,332
Aggregate Intrinsic Value Options exercisable	31,758
Aggregate Intrinsic Value Options vested, exercisable and options expected to vest	$ 60,090

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Number of Shares, Warrants Outstanding, Beginning balance	1,645,500	80,000
Number of Shares, Warrants Granted	1,607,000	1,621,500
Number of Shares, Warrants Exercised	(201,900)	(56,000)
Number of Shares, Warrants Forfeited or Cancelled
Number of Shares, Warrants Outstanding, Ending balance	3,050,600	1,645,500
Weighted Average Exercise Price, Warrants outstanding, Beginning balance	$ 3.97	$ 2
Weighted Average Exercise Price, Warrants Granted	1.30	4
Weighted Average Exercise Price, Warrants Exercised	1.19	2
Weighted Average Exercise Price, Warrants Forfeited or cancelled
Weighted Average Exercise Price, Warrants outstanding, Ending balance	$ 2.75	$ 3.97
Weighted Average Remaining Contractual Life (Years), Warrants outstanding, Beginning balance	4 years 1 month 9 days	2 years 9 months 14 days
Weighted Average Remaining Contractual Life (Years), Warrants Grants	4 years 7 months 21 days	4 years 1 month 24 days
Weighted Average Remaining Contractual Life (Years), Warrants outstanding, Ending balance	3 years 10 months 10 days	4 years 1 month 9 days

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 10,027,000
Tax expiration description	expire in various years through 2038
Valuation allowance	$ 2,123,700	$ 2,929,900

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
NOL carryover	$ 2,105,600	$ 2,929,900
Depreciation	18,100
Valuation allowance	(2,123,700)	(2,929,900)
Net deferred tax asset

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of the Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Book Loss	$ (1,170,600)	$ (1,556,355)
Depreciation	13,400
Meals & Entertainment	2,600	3,200
Stock Compensation	242,730
Loss on Asset Disposal	7,714
Change in valuation allowance	904,156	1,553,200
Provision for Income Taxes

Income Taxes - Schedule of Re_2

Income Taxes - Schedule of Reconciliation of the Provision for Income Taxes (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal statutory tax rate	34.00%	34.00%

Loss Per Share (Details Narrati

Loss Per Share (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	May 31, 2018
Warrants Outstanding			24,000
Convertible note payable	$ 50,000	$ 100,000
Common stock, shares outstanding	8,776,629	4,978,929
Stock Option [Member]
Warrants Outstanding	826,267	299,938
Conversion of common stock	826,267	299,938
Common stock, shares outstanding	3,901,867	1,783,938
Convertible Debt [Member]
Convertible note payable	$ 50,000	$ 100,000
Convertible common stock shares	25,000	50,000
Warrant [Member]
Warrants Outstanding	3,050,600	1,434,000
Conversion of common stock	3,050,600	1,434,000

Loss Per Share - Schedule of Ea

Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Loss from continuing operations available to common stockholders (numerator)	$ (5,574,163)	$ (4,424,503)
Weighted average number of common shares outstanding used in loss per share during the period (denominator)	6,898,047	4,403,479

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Expense form operating leases	$ 70,187	$ 59,700
Non-cancellable operating leases	$ 42,630
Minimum lease payments description	The future minimum lease payments are due during the year 2019.

Concentrations - Schedule of Co

Concentrations - Schedule of Concentration of Risks (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues [Member] | Customer A [Member]
Percentage of revenues	23.34%	0.77%
Revenues [Member] | Customer B [Member]
Percentage of revenues	12.87%	0.00%
Revenues [Member] | Customer C [Member]
Percentage of revenues	12.62%	0.00%
Revenues [Member] | Customer D [Member]
Percentage of revenues	12.18%	28.75%
Revenues [Member] | Customer E [Member]
Percentage of revenues	0.94%	19.83%
Revenues [Member] | Customer F [Member]
Percentage of revenues	0.21%	14.23%
Revenues [Member] | Customer G [Member]
Percentage of revenues	0.00%	12.85%
Accounts Receivable [Member] | Customer A [Member]
Percentage of revenues	64.43%	0.00%
Accounts Receivable [Member] | Customer B [Member]
Percentage of revenues	17.01%	0.00%
Accounts Receivable [Member] | Customer C [Member]
Percentage of revenues	12.11%	0.00%
Accounts Receivable [Member] | Customer D [Member]
Percentage of revenues	0.00%	44.34%
Accounts Receivable [Member] | Customer E [Member]
Percentage of revenues	0.00%	23.21%
Accounts Receivable [Member] | Customer F [Member]
Percentage of revenues	0.00%	21.33%

Joint Venture (Details Narrativ

Joint Venture (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)
Equity Method Investments and Joint Ventures [Abstract]
Loss on investment	$ 105

Defined Contribution Plan (Deta

Defined Contribution Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Defined Contribution Plan
Contribution plan description	The Company has elected to match 100% of each participant's contribution up to 3% of salary, and 50% of the next 2% of salary contributed. The Company may also elect, on an annual basis, to make a discretionary contribution to the plan. Company matches and elective contributions vest to participant accounts as follows: 20% after two years of service, and 20% per year thereafter until the participant reaches 6 years of service, at which time, employer contributions vest 100%.
Cost of contribution	$ 51,415	$ 33,725

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Oct. 10, 2018	Oct. 17, 2016	Dec. 31, 2018
Severance expense	$ 224,818
Paid out obligation amount			$ 40,862
Remaining obligation amount			183,956
Payment for services		$ 500,000
Consulting Agreement [Member] | Mr Mark Cola [Member]
Agreement term	1 year
Non-exclusive consulting services	$ 250
Payment for services			2,678
Nineteen Semi-Monthly Installments [Member] | October 1, 2019 [Member]
Total installments amount			9,367
Nineteen Semi-Monthly Installments [Member] | October 15, 2019 [Member]
Total installments amount			$ 5,983

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 15, 2019	Mar. 09, 2019	Feb. 28, 2019	Jan. 31, 2019	Dec. 31, 2018	Oct. 31, 2018	Jun. 30, 2018	May 31, 2018	May 31, 2018	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Common stock, shares issued					177,900	177,900	2,040,000	1,000,000	29,800		3,901,867	1,783,938
Exercise of warrants								24,000	24,000
Subsequent Event [Member]
Common stock, shares issued	1,400,800		67,830	67,830
Exercise price per shares			$ 1.08	$ 1.08
Exercise of warrants	420,240		67,830	67,830
Proceeds from issuance of stock	$ 1,679,230		$ 73,256	$ 73,256
Subsequent Event [Member] | June 2018 Public Offering [Member]
Common stock, shares issued				90,831
Subsequent Event [Member] | 2013 Equity Incentive Plan [Member]
Option purchase shares of common stock				99,376
Exercise price per shares				$ 1.50
Subsequent Event [Member] | Non-Employee Director 1 [Member] | 2013 Equity Incentive Plan [Member]
Common stock, shares issued				50,000
Subsequent Event [Member] | Non-Employee Director 2 [Member] | 2013 Equity Incentive Plan [Member]
Common stock, shares issued				50,000
Subsequent Event [Member] | Non-Employee Director 3 [Member] | 2013 Equity Incentive Plan [Member]
Common stock, shares issued				50,000
Subsequent Event [Member] | Non-Employee Director 4 [Member] | 2013 Equity Incentive Plan [Member]
Common stock, shares issued				50,000
Subsequent Event [Member] | Vice President Member]
Common stock, shares issued		1,500
Exercise price per shares				$ 2.02
Vested option to purchase shares of common stock				11,832
Subsequent Event [Member] | Mr John Rice [Member] | 2013 Equity Incentive Plan [Member] | Option 1 [Member]
Option purchase shares of common stock										22,916
Exercise price per shares										$ 1.50
Subsequent Event [Member] | Mr John Rice [Member] | 2013 Equity Incentive Plan [Member] | Option 2 [Member]
Option purchase shares of common stock										22,916
Exercise price per shares										$ 1.9262
Subsequent Event [Member] | Mr John Rice [Member] | 2013 Equity Incentive Plan [Member] | Option 3 [Member]
Option purchase shares of common stock										22,916
Exercise price per shares										$ 2.04